YACHT-CLUB-DE-MONACO
As the curtain fell on the 11th Monaco Energy Boat Challenge, combining Tech Talks and on-water contests that saw 40 universities and 450 students from 25 nations showcasing their progress in alternative propulsion technology, Yacht Club de Monaco continues to support innovation in pursuit of sustainability in the yachting sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724805334/en/
Design, innovate and build an ecosystem that invests in green solutions. ©Mesi / YCM
“Preserving the environment is at the heart of what most concerns us. Protecting our planet’s rich yet fragile marine ecosystem is our top priority. If you want to raise the bar, you have to become an agent of change,” says YCM President, HSH Prince Albert II of Monaco, when outlining the roadmap.
This commitment is reflected in the SEA Index®, a benchmark measuring the environmental impact of yachts (+25m), available to owners and shipyards, and is now applied in 15 harbors and marinas from Menton to Saint-Tropez, Corsica, and those operated by SEPM in Monaco.
Determined to support innovation across the board in this sector, YCM is now gearing up to host the Monaco Smart & Sustainable Marina Rendezvous on 22-23 September 2024, organised by Monaco Marina Management (M3).
Under the aegis of the collective ‘Monaco, Capital of Advanced Yachting’ initiative, the meeting is supported by Prince Albert II of Monaco Foundation and the Principality’s digital transition programme Extended Monaco, alongside UBS, Sanlorenzo, MB92 Group and Bombardier. “Our main driver of innovation is sustainability and we are delighted to support this event once again this year. Taking part in this meeting of the brightest and boldest minds and witnessing the innovative and tangible solutions that are brought forward give us optimism and confidence to define a new norm for the future” says Emmanuel Bornand, Vice President, International Business Aircraft Sales, Bombardier.
Monaco Smart & Sustainable Marina: an ecosystem driving change in marinas
Organised by Monaco Marina Management (M3), this 4th edition will gather 250+ delegates at the YCM, including entrepreneurs, industrialists, investors, promoters and marina developers from all over the world. An exhibition area provides an opportunity for all to see and test the latest innovations from the selected startups and scaleups.
“Faced with today’s environmental challenges, we firmly believe the key is to put innovators in direct contact with marina operators and other professionals in the sector to get technological solutions in place. Together, thanks to everyone’s expertise, we can create marinas that are models of sustainable excellence,” explains José Marco Casellini, CEO of M3, a Monaco-based consultancy specialising in development, management and promotion of marinas, yacht clubs and sailing schools.
Getting experts to interact via workshops
Three key topics will be debated at workshops: energy transition and sustainability, including greener fuels and waste reduction; building resilient, energy-efficient infrastructure; and diversifying marina services. The main objectives are to encourage collaboration, develop sustainable strategies, and drive the adoption of best practices in sustainable marina management.
Keynote presentations: understanding the challenges
During the meeting there will be three keynote talks exploring how technology, the banking sector and architecture can transform marinas. Discussions will focus on optimising user experience with advanced technologies; the role of financial institutions in the sustainable approach to marinas; and the importance of innovative architecture design to create marinas that are not only efficient and appealing but also respect the environment.
Architecture: call for ideas in eco-sensitive areas
This year, architects and students are invited to submit designs for a floating marina in ecologically sensitive areas. A jury, chaired by the Zaha Hadid Architects firm, alongside Jean-Michel Wilmotte and experts, will assess the projects. The goal is to create avant-garde solutions that respect the environment and meet modern marina demands. The location will be revealed in the coming days.
International Smart & Sustainable Marina Awards: rewarding ecosystem recognition
At the end of two days of exchanges and networking, the International Smart & Sustainable Marina Awards will be presented on Monday 23rd September 2024 at 4.00pm to the winners in three categories: Startups & Scaleups, Marinas, and Architects (professionals & students).
It is through events and initiatives like these that Yacht Club de Monaco maintains its role as leader in innovation, by connecting the whole maritime ecosystem to push for a more sustainable future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724805334/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom